PREVNAR 13

Google image searchProduct monograph

Active ingredients

pneumococcal polysaccharide serotype 1, 2.2 MCG/0.5 ML

pneumococcal polysaccharide serotype 3, 2.2 MCG/0.5 ML

pneumococcal polysaccharide serotype 4, 2.2 MCG/0.5 ML

pneumococcal polysaccharide serotype 5, 2.2 MCG/0.5 ML

pneumococcal polysaccharide serotype 6a, 2.2 MCG/0.5 ML

pneumococcal polysaccharide serotype 6b, 4.4 MCG/0.5 ML

pneumococcal polysaccharide serotype 7f, 2.2 MCG/0.5 ML

pneumococcal polysaccharide serotype 9v, 2.2 MCG/0.5 ML

pneumococcal polysaccharide serotype 14, 2.2 MCG/0.5 ML

pneumococcal polysaccharide serotype 18c, 2.2 MCG/0.5 ML

pneumococcal polysaccharide serotype 19a, 2.2 MCG/0.5 ML

pneumococcal polysaccharide serotype 19f, 2.2 MCG/0.5 ML

pneumococcal polysaccharide serotype 23f, 2.2 MCG/0.5 ML

corynebacterium diphtheriae crm-197 protein, 34 MCG/0.5 ML

DIN: 02335204

Dosage form(s): SUSPENSION

Route(s) of administration: INTRAMUSCULAR

Schedule: Schedule D

Company: PFIZER CANADA ULC

Date: 25-OCT-2012

ATC:

Reference brand drug: Capvaxive, Prevnar 13, Prevnar 20, Synflorix, Vaxneuvance

Search on Google